UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1018-13
Program Prior Authorization/Notification
Medication Cinryze® (C1 esterase inhibitor, human)
P&T Approval Date 11/2013, 8/2014, 8/2015, 7/2016, 7/2017, 7/2018, 7/2019, 7/2020, 7/2021,
7/2022, 7/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Cinryze is a plasma-derived C1 esterase inhibitor (human) indicated for routine prophylaxis
against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and
older) with hereditary angioedema (HAE).1
2. Coverage Criteriaa:
A. Cinryze will be approved based on all of the following criteria:
1. Diagnosis of hereditary angioedema (HAE)
-AND-
2. For prophylaxis against HAE attacks
-AND-
3. Not used in combination with other products indicated for prophylaxis against HAE attacks
(e.g., Haegarda, Takhzyro, Orladeyo)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Medical Necessity and supply limits may be in place.
4. References:
1. Cinryze [package insert]. Lexington, MA: ViroPharma Biologics LLC; November 2024.
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification - Cinryze (C1 esterase inhibitor,
human)
Change Control
11/2013 New program.
8/2014 Annual review. Added new criterion that concomitant acute therapies
cannot be used. Decreased authorization from 60 months to 12 months.
Updated reference.
8/2015 Annual review. No change.
7/2016 Annual review with no changes to the coverage criteria. Updated
background and references.
7/2017 Annual review with no changes to the coverage criteria. Updated
references.
7/2018 Annual review. Updated coverage criteria.
7/2019 Annual review with no changes to coverage criteria. Updated
background and references.
7/2020 Annual review. Removed criteria for acute attacks. Updated
background and references.
7/2021 Annual review. Updated combination use criteria to include all
prophylaxis agents. Updated references and background.
7/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote.
7/2023 Annual review. Revised wording of criteria without change to clinical
intent. Updated reference.
3/2024 Annual review. No changes to coverage criteria.
3/2025 Annual review. No changes to coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
2